Published Date: 02 Mar 2023
Obese women change the structure of the placenta (an important substance that provides nourishment to the baby during pregnancy) more than gestational diabetes (GDM; poor blood sugar control during pregnancy) boy).
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Unified Neuro/Psych Residency Program: New Proposal.
2.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
3.
What is Mohs micrographic surgery? 8 FAQs about Mohs
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
1.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
2.
The Unseen Threat: Uncovering the Risks of Pancoast Tumor
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
5.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Efficient Management of First line ALK-rearranged NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation